Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| mTOR signaling pathway | R-HSA-165662 | map04150 | cefepime | 3035905 | drug-path |
| Homologous recombination | R-HSA-5685942 | map03440 | aminoglutethimide | 2145 | drug-path |
| Shigellosis | 0 | map05131 | Prestwick-1085 | None | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | Prestwick-1085 | None | drug-path |
| Gap junction | R-HSA-190861 | map04540 | Prestwick-1085 | None | drug-path |
| Ubiquitin mediated proteolysis | R-HSA-983153 | map04120 | Prestwick-1085 | None | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | Prestwick-1085 | None | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | Prestwick-1085 | None | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | Prestwick-1085 | None | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | denatonium benzoate | 4628 | drug-path |
| ErbB signaling pathway | R-HSA-168638 | map04012 | denatonium benzoate | 4628 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | denatonium benzoate | 4628 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | denatonium benzoate | 4628 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | denatonium benzoate | 4628 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | denatonium benzoate | 4628 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | denatonium benzoate | 4628 | drug-path |
| Asthma | R-HSA-444620 | map05310 | denatonium benzoate | 4628 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | denatonium benzoate | 4628 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | denatonium benzoate | 4628 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | denatonium benzoate | 4628 | drug-path |